Compare MakeMyTrip Ltd (MMYT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Pfizer Inc — how do they compare? MakeMyTrip Ltd trades at $60.11 (market cap $5.78B), while Pfizer Inc trades at $26.34 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 26.3× MakeMyTrip Ltd's market cap, and Pfizer Inc pays a 6.46% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| MMYT | PFE | |
|---|---|---|
Market Cap | $5.78B | $151.73B |
Sector | Technology | Health |
52-Week High | $103.21 | $28.56 |
52-Week Low | $36.30 | $23.60 |
Enterprise Value | $6.44B | $203.22B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $60.30, down 1.0% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2027 earnings that beat expectations despite revenue headwinds, maintaining robust gross margins of 73.45%. Recent news highlights growth in hotels and packages segments offsetting air travel softness, with analyst consensus strongly bullish at 73% buy ratings.
The outlook remains positive with earnings momentum and diversified travel services driving growth, though elevated P/E ratio of 267 and geopolitical travel disruptions present risks. Institutional sentiment supports upside potential with 34% average price target, while balance sheet strength provides stability amid market volatility.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
